<DOC>
	<DOCNO>NCT02472002</DOCNO>
	<brief_summary>MES-HT pilot multicenter prospective study conduct transplant patient develop severe coronary vasculopathy . A preparation autologous mesenchymal cell bone marrow administer endomyocardial injection , guide Noga® cardiac mapping system . The main objective determine effect administration autologous mesenchymal cell bone marrow intramyocardial injection myocardial perfusion cardiac transplant patient severe coronary vasculopathy .</brief_summary>
	<brief_title>Mesenchymal Stem Cell Administration Treatment Coronary Graft Disease Heart Transplant Patients</brief_title>
	<detailed_description>MES-HT phase 1-2 multicenter pilot prospective study conduct 14 heart transplant patient develop severe coronary vasculopathy , aim ass effect myocardial perfusion intramyocardial administration percutaneous way autologous mesenchymal stem cell derive bone marrow . The main objective show improvement myocardial perfusion non-randomized uncontrolled pilot study , consider randomize control study . The administration intra myocardial cell use NOGA system carry date 1,000 patient consider feasible safe . However , investigator assess carefully feasibility safety invasive approach . The primary endpoint improvement myocardial perfusion measure MRI endomyocardial injection mesenchymal cell percutaneous way , guide NOGA system . The secondary endpoint feasibility safety administration , change ejection fraction measure contrast echocardiography , change MRI cardiac parameter ( leave ventricular volume , intramyocardial fibrosis ) , oxygen consumption exercise , myocardial perfusion measure SPECT . Other secondary endpoint evolution immune status , histological criterion myocardial biopsy . Once map perform , preparation inject another catheter ( MYOSTAR injection catheter ) also guide Noga® system . This catheter may position region interest ( viable ischemic area ) allow injection quantity CSM ( 40 million / ml ) 10 12 different injection point injection volumes 0.3 ml total dose 120 144 million cell . After injection procedure , patient monitor 48 hour minimum clinically continuous ECG monitoring detect possible arrhythmia . A troponin dosage do 6 H , 24 48 hour . An echocardiogram perform immediately procedure release 48 H. A clinical evaluation make patient discharge 1 month ( clinical examination + Holter + echocardiography ) , 3 month ( examination ) , 6 month ( clinical examination , Holter , echocardiography , cardiac MRI , test effort measurement VO2 , effort myocardial tomoscintigraphy patient Pitie-Salpetriere hospital , Rubidium 82 positron emission tomography ) 12 month ( examination ) . Myocardial biopsy control coronary angiography perform within 12 month accordance practice team . Patients benefit biological monitoring provide monitor immune response . This immuno-monitoring ass possible influence injection mesenchymal cell immunological tolerance mechanism . It implement balance sheet cardiac tissue wan annual biopsy peripheral blood sample inclusion , 48 hour injection 1 month , 3 month 6 month . The limit toxicity define occurrence one month serious adverse effect relate protocol , require hospitalization able life-threatening , like abundant pericardial effusion require pericardial drainage , bleed complication require blood cell transfusion surgery , stroke constitute , sepsis septic shock , cardiogenic shock , severe ventricular rhythm refractory death . All patient follow one year .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Cardiac transplant patient whatever initial pathology 2 . Coronary vasculopathy grade 3 ( CAV3 ) define : Stenosis &gt; 50 % commoncore ( CT ) stenosis &gt; 70 % least 2 3 main coronary artery stenosis &gt; 70 % secondary branch 3 territory . Coronary vasculopathy grade 1 2 ( CAV 1 2 ) associate FELV ( FEVG ) dysfunction &lt; 45 % abnormality completion restrictive type . 3 . Defect drip least 2 segments/17 stress MRI . 4 . Fraction ejection LV &lt; 50 measure ultrasound examination confusion diastolic function define restrictive mitral steam ( E/A &gt; 2 E/A 1 2 deceleration time E &lt; 150 m ) leave ventricular diastolic pressure measure coronarography &gt; 16mg Hg . 5 . Without sign acute rejection time inclusion . 6 . Under optimal medical treatment 7 . Patient give enlightened sign consent Exclusion criterion : 1 . Patients &lt; 18 ou &gt; 80 year 2 . Acute coronary syndrome revascularisation 3 last month 3 . Acute cardiac rejection 3 last month 4 . Atrial fibrillation 5 . Claustrophobia contraindication MRI ( ex : pacemaker ) , contrast injection adenosine . 6 . Presence thrombus leave cavity detect ultrasound examination MRI realize injection.. 7 . Pregnant breastfeed woman 8 . Woman old enough reproduction without effective mean contraception participation study 9 . Patient benefit legal protective measure 10 . HIV positive 11 . Not membership national save insurance ( beneficiary legal successor ) 12 . Patients undergo others biomedical research 13 . Patient understanding procedure bound protocol 14 . Bad adhesion protocol suspect investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Transplant coronary disease</keyword>
	<keyword>Mesenchymal cell therapy</keyword>
	<keyword>Administration CSM NOGA system</keyword>
	<keyword>Coronary disease heart transplant patient</keyword>
</DOC>